Curis Stock Is A Speculative Play That Could Produce Solid Returns (NASDAQ:CRIS)
seekingalpha.com
news
2022-10-21 14:18:54

Morsa Images Curis, Inc. (NASDAQ:CRIS) is a small biotech company that is working on developing drugs to treat cancer. It has gotten hammered in 2022, plunging from a 52-week high of $7.63, to a low of $0.68. As I write it's trading at $0.7148. Its market cap has also plunged to $67.69 million. The only thing approved for Curis is ErivedgeÂ®, a tiny molecule drug that is orally administered. It's approved for use in advanced basal cell carcinoma or BCC and medulloblastomas. This is the only source of revenue for the company, which it receives from a licensing agreement with Genentech and Roche.
